Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
All articles by Brian Park, PharmD
Enhertu Approved to Treat HER2-Positive Breast Cancer Following 2 or More Prior Anti-HER2 Therapies
Results showed a confirmed ORR of 60.3% including a 4.3% complete response rate and 56.0% partial response rate, with a median DOR of 14.8 months.
Microbiome-Derived Therapy Gets Orphan Drug Status for Hepatocellular Carcinoma
SFA001 blocked the progression of hepatitis B to HCC in transgenic HBX animal models
- Loading...
Loading...
Next post in Gastrointestinal Cancers
Loading... 
Loading...